I guess this should be on a genomics thread, but
what the heck, we wander all over SI with our
chit chat: What I'd like to see, to value GLGC,
Curagen and the likes--is the marketcap per
SNP (where a Genset might look like a good value)
or the maretcap compared to number of database
subscriptions, where glgc or incy might look
particularly strong, or the cap per base pair
patented, hmmm. It is too complicated for the
casual trader--which is part of the reason one
becomes an investor in some of these (wish I'd
been a better investor with glgc, shit!)--you
buy and wait for the Street to discover your
company's story, patience is key. Well, I suppose
no patience is required to do the momentum thing,
I must just have some sort of a mental block
on that--I hate to chase anything (for instance,
it will be increasingly frustrating to watch nbix
cruise on up to $50, while I sit on my snap).
Of course I cant beat myself up too much--I'd
probably have sold glgc after a triple and not
made all that much anyway--not one to let profits
run as much as I should. I expect glgc is going
to $100 now, a nice even number for the traders
to shoot for. |
